SCRN compared to THRM spWhat is wrong with this picture ?
SCRN last quarter revenue = 6.8 million dollars !! sp =0.05
While SCRN is making money THRM has an operating loss of 10 million dollars and some great potential (CEO'own words) sp=.41
Granted the float is smaller nevertheless but even at 2:1 ratio SCRN should be at .20 if compared to THRM at today's prices .
THRM = an excerpt taken from the interview with THRM CEO Rob Fia on stockhouse
SH: And finally, Rob, if there’s anything I’ve overlooked please feel free to elaborate.
RF: Dave, you know, I would say focus on this clinical study. We're excited to get those results out, right behind that, the FDA-EUA submission, which is very exciting for us, we have customer demand all over the world, as I mentioned. We have one customer that's offered to provide 100% of the cost of the product to get that product in their hands as quickly as possible for schools in Europe, and then I think we've got some great potential with the Venowave product to be able to distribute that in the US and the other point I'd make is that, you know, the company is sitting on about 10 million in operating losses. So as we start generating revenue and cashflow and profit, we'll have a lot of tax advantages going forward.